• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Stocks That Hit 52-Week Lows On Thursday

    7/20/23 2:01:19 PM ET
    $ACGN
    $APLS
    $APM
    $ASTI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ACGN alert in real time by email

     

    During Thursday's session, 40 stocks hit new 52-week lows.

    52-Week Low Highlights:

    • The largest company by market cap to set a new 52-week low was Crown Castle (NYSE:CCI).
    • The smallest company by market cap to set a new 52-week low was Ucommune International (NASDAQ:UK).
    • Vir Biotechnology (NASDAQ:VIR)'s stock fell the most, as it traded down 44.38% to reach a new 52-week low.
    • Yunji (NASDAQ:YJ)'s stock rebounded the most, as it traded up 0.0% after dropping to a new 52-week low.

    Here are all the stocks that set new 52-week lows on Thursday:

    • Crown Castle (NYSE:CCI) shares set a new 52-week low of $103.22. The stock traded down 5.62%.
    • Kenvue (NYSE:KVUE) stock broke to a new 52-week low of $22.49 on Thursday. Shares of the company traded down 3.06%.
    • SBA Comms (NASDAQ:SBAC) stock drifted down 7.65% on Thursday morning to hit a new 52-week low of $214.56.
    • NovoCure (NASDAQ:NVCR) shares set a new 52-week low of $38.29. The stock traded up 0.28%.
    • Apellis Pharmaceuticals (NASDAQ:APLS) stock set a new 52-week low of $34.71 on Thursday, moving down 12.81%.
    • Cedar Fair (NYSE:FUN) stock hit a yearly low of $36.44. The stock was down 1.21% for the day.
    • Vir Biotechnology (NASDAQ:VIR) shares reached a new 52-week low of $12.56 on Thursday morning, moving down 44.38%.
    • Nu Skin Enterprises (NYSE:NUS) stock hit a new 52-week low of $28.50. The stock was down 1.73% on the session.
    • Monro (NASDAQ:MNRO) stock hit a yearly low of $38.21. The stock was down 0.94% for the day.
    • SIGNA Sports United (NYSE:SSU) stock drifted down 5.22% on Thursday morning to hit a new 52-week low of $2.51.
    • Silk Road Medical (NASDAQ:SILK) shares hit a yearly low of $19.93. The stock was down 1.76% on the session.
    • Beneficient (NASDAQ:BENF) stock hit a new 52-week low of $2.16. The stock was down 10.7% on the session.
    • uniQure (NASDAQ:QURE) shares hit a yearly low of $10.08. The stock was down 0.1% on the session.
    • Sohu.com (NASDAQ:SOHU) shares moved down 0.78% on Thursday to hit a new 52-week low of $10.73, drifting down 0.78%.
    • FibroGen (NASDAQ:FGEN) shares were down 2.58% for the day, having made a 52-week low of $2.29.
    • Richardson Electronics (NASDAQ:RELL) stock achieved a new 52-week low on Thursday morning, hitting $12.80 and moving down 10.83%.
    • NioCorp Developments (NASDAQ:NB) shares made a new 52-week low of $4.57 on Thursday. The stock was down 2.66% for the day.
    • OrganiGram Holdings (NASDAQ:OGI) stock achieved a new 52-week low on Thursday morning, hitting $1.34 and moving down 4.96%.
    • Destra Multi-Alternative (NYSE:DMA) shares reached a new 52-week low of $4.82 on Thursday morning, moving down 1.01%.
    • Yunji (NASDAQ:YJ) shares hit a yearly low of $1.21. The stock was 0.0% (flat) on the session.
    • Aspira Womens Health (NASDAQ:AWH) shares were down 31.66% for the day, having made a 52-week low of $2.62.
    • Strong Global (AMEX:SGE) shares set a new 52-week low of $2.70. The stock traded down 0.84%.
    • Golden Sun Education Gr (NASDAQ:GSUN) stock drifted up 2.28% on Thursday morning to hit a new 52-week low of $0.91.
    • AERWINS Technologies (NASDAQ:AWIN) shares hit a yearly low of $0.27. The stock was down 9.02% on the session.
    • ShiftPixy (NASDAQ:PIXY) shares hit a yearly low of $1.23. The stock was down 6.9% on the session.
    • Treasure Global (NASDAQ:TGL) shares set a new yearly low of $0.72 this morning. The stock was down 2.99% on the session.
    • Aceragen (NASDAQ:ACGN) shares reached a new 52-week low of $1.21 on Thursday morning, moving down 13.19%.
    • Aptorum Gr (NASDAQ:APM) shares made a new 52-week low of $2.09 on Thursday. The stock was down 0.96% for the day.
    • JE Cleantech Hldgs (NASDAQ:JCSE) shares were down 5.39% for the day, having made a 52-week low of $0.41.
    • Mallinckrodt (AMEX:MNK) stock hit a yearly low of $0.56. The stock was down 13.75% for the day.
    • Ascent Solar Technologies (NASDAQ:ASTI) shares hit a yearly low of $0.08. The stock was down 2.37% on the session.
    • 9 Meters Biopharma (NASDAQ:NMTR) stock drifted down 7.44% on Thursday morning to hit a new 52-week low of $0.15.

    Be sure to monitor Benzinga for the news traders need! And for even more up-to-date info on 52-week lows and highs, check out Benzinga Pro. This cutting-edge market research platform alerts traders of which stocks are trading near their 52-week highs and lows each morning - and delivers lots of other actionable data. Learn more here.

    Get the next $ACGN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ACGN
    $APLS
    $APM
    $ASTI

    CompanyDatePrice TargetRatingAnalyst
    Ascent Solar Technologies Inc.
    $ASTI
    4/23/2026$20.00Buy
    H.C. Wainwright
    SBA Communications Corporation
    $SBAC
    4/22/2026$247.00Hold → Buy
    Truist
    SBA Communications Corporation
    $SBAC
    3/31/2026$193.00Hold
    Truist
    Crown Castle Inc.
    $CCI
    3/31/2026$90.00Hold
    Truist
    Crown Castle Inc.
    $CCI
    3/23/2026$85.00Overweight → Equal Weight
    Wells Fargo
    Apellis Pharmaceuticals Inc.
    $APLS
    3/13/2026$31.00Buy
    Roth Capital
    uniQure N.V.
    $QURE
    3/11/2026$35.00Neutral → Outperform
    Mizuho
    uniQure N.V.
    $QURE
    3/9/2026$60.00Equal Weight → Overweight
    Wells Fargo
    More analyst ratings

    $ACGN
    $APLS
    $APM
    $ASTI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    PRESIDENT Watson Robert A. bought $4,639 worth of shares (537 units at $8.64), increasing direct ownership by 3% to 17,297 units (SEC Form 4)

    4 - Destra Multi-Alternative Fund (0001523289) (Issuer)

    3/2/26 4:35:44 PM ET
    $DMA
    Trusts Except Educational Religious and Charitable
    Finance

    President and CEO Fitzsimmons Peter D bought $250,879 worth of shares (12,750 units at $19.68), increasing direct ownership by 13% to 112,033 units (SEC Form 4)

    4 - MONRO, INC. (0000876427) (Issuer)

    2/9/26 3:51:15 PM ET
    $MNRO
    Automotive Aftermarket
    Consumer Discretionary

    President and CEO Fitzsimmons Peter D bought $251,017 worth of shares (13,350 units at $18.80), increasing direct ownership by 16% to 99,283 units (SEC Form 4)

    4 - MONRO, INC. (0000876427) (Issuer)

    2/5/26 3:32:45 PM ET
    $MNRO
    Automotive Aftermarket
    Consumer Discretionary

    $ACGN
    $APLS
    $APM
    $ASTI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Hicks Mack H.

    3 - Beneficient (0001775734) (Issuer)

    4/20/26 7:01:44 PM ET
    $BENF
    Finance: Consumer Services
    Finance

    SEC Form 4 filed by Haddrill Richard M

    4 - Six Flags Entertainment Corporation/NEW (0001999001) (Issuer)

    4/20/26 5:48:10 PM ET
    $FUN
    Services-Misc. Amusement & Recreation
    Consumer Discretionary

    SEC Form 4 filed by Sullivan Timothy Eugene

    4 - Apellis Pharmaceuticals, Inc. (0001492422) (Issuer)

    4/20/26 4:02:06 PM ET
    $APLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACGN
    $APLS
    $APM
    $ASTI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Yunji Files 2025 Annual Report on Form 20-F

    HANGZHOU, China, April 24, 2026 /PRNewswire/ -- Yunji Inc. ("Yunji" or the "Company") (NASDAQ:YJ), a leading membership-based social e-commerce platform, today announced that it has filed its annual report on Form 20-F for the fiscal year ended December 31, 2025 with the Securities and Exchange Commission on April 24, 2026 Eastern Time. The annual report can be accessed on the Company's investor relations website at https://investor.yunjiglobal.com. The Company will provide a hard copy of its annual report containing the audited consolidated financial statements, free of charge, to its shareholders and ADS holders upon request. Requests should be submitted to [email protected] Yunji

    4/24/26 7:30:00 AM ET
    $YJ
    Other Specialty Stores
    Consumer Discretionary

    Kenvue to Announce First Quarter 2026 Results on May 7, 2026

    Kenvue Inc. (NYSE:KVUE) will announce its first quarter 2026 financial results before the market opens on May 7, 2026. Due to the pending transaction with Kimberly-Clark, Kenvue will not be hosting a quarterly conference call to review its financial results. The press release will be available on the company's website at investors.kenvue.com. About Kenvue Kenvue Inc. is the world's largest pure-play consumer health company by revenue. Built on more than a century of heritage, our iconic brands, including Aveeno®, BAND-AID® Brand, Johnson's®, Listerine®, Neutrogena® and Tylenol®, are science-backed and recommended by healthcare professionals around the world. At Kenvue, we realize the

    4/23/26 4:32:00 PM ET
    $KVUE
    Specialty Chemicals
    Consumer Discretionary

    Vir Biotechnology to Host Conference Call for First Quarter 2026 Financial Results

    Vir Biotechnology, Inc. (NASDAQ:VIR), today announced that it will host a conference call at 4:30 p.m. ET / 1:30 p.m. PT on Wednesday, May 6 to provide a corporate update and discuss its financial results for the first quarter ended March 31, 2026. The conference call may be accessed on the Events & Presentations page of the Vir Biotechnology website. About Vir Biotechnology Vir Biotechnology, Inc. is a clinical-stage biopharmaceutical company focused on powering the immune system to transform lives by discovering and developing medicines for serious infectious diseases and cancer. Its clinical-stage portfolio includes programs for chronic hepatitis delta and multiple PRO-XTEN® dual-mas

    4/23/26 4:05:00 PM ET
    $VIR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ACGN
    $APLS
    $APM
    $ASTI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    H.C. Wainwright initiated coverage on Ascent Solar with a new price target

    H.C. Wainwright initiated coverage of Ascent Solar with a rating of Buy and set a new price target of $20.00

    4/23/26 7:55:25 AM ET
    $ASTI
    Semiconductors
    Technology

    SBA Comm upgraded by Truist with a new price target

    Truist upgraded SBA Comm from Hold to Buy and set a new price target of $247.00

    4/22/26 7:43:50 AM ET
    $SBAC
    Real Estate Investment Trusts
    Real Estate

    Truist initiated coverage on SBA Comm with a new price target

    Truist initiated coverage of SBA Comm with a rating of Hold and set a new price target of $193.00

    3/31/26 8:18:04 AM ET
    $SBAC
    Real Estate Investment Trusts
    Real Estate

    $ACGN
    $APLS
    $APM
    $ASTI
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    October 18, 2024 - FDA Roundup: October 18, 2024

    For Immediate Release: October 18, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  This week, FDA continues ongoing efforts to increase access and supply of IV and peritoneal dialysis (PD) fluids following Hurricane Helene-related damage to Baxter International Inc.’s facility in Marion, North Carolina. Specifically, FDA acted quickly to c

    10/18/24 4:16:25 PM ET
    $NVCR
    $BAX
    Medical/Dental Instruments
    Health Care

    FDA Approval for EMPAVELI issued to APELLIS PHARMACEUTICALS INC

    Submission status for APELLIS PHARMACEUTICALS INC's drug EMPAVELI (ORIG-1) with active ingredient PEGCETACOPLAN has changed to 'Approval' on 05/14/2021. Application Category: NDA, Application Number: 215014, Application Classification: Type 1 - New Molecular Entity

    5/17/21 11:09:40 AM ET
    $APLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACGN
    $APLS
    $APM
    $ASTI
    SEC Filings

    View All

    SEC Form 20-F filed by Yunji Inc.

    20-F - Yunji Inc. (0001759614) (Filer)

    4/24/26 6:32:51 AM ET
    $YJ
    Other Specialty Stores
    Consumer Discretionary

    Crown Castle Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - CROWN CASTLE INC. (0001051470) (Filer)

    4/22/26 4:16:44 PM ET
    $CCI
    Real Estate Investment Trusts
    Real Estate

    SEC Form 40-17G filed by Destra Multi-Alternative Fund

    40-17G - Destra Multi-Alternative Fund (0001523289) (Filer)

    4/22/26 10:31:47 AM ET
    $DMA
    Trusts Except Educational Religious and Charitable
    Finance

    $ACGN
    $APLS
    $APM
    $ASTI
    Leadership Updates

    Live Leadership Updates

    View All

    Organigram Announces Shareholder Approval of Acquisition of Sanity Group GmbH and Results of its Annual General and Special Meeting

    Organigram Global Inc. (NASDAQ:OGI) (TSX:OGI), (the "Company" or "Organigram"), is pleased to announce that the shareholders of Organigram have overwhelmingly approved the resolution required to consummate the previously announced acquisition by the Company (the "Transaction") of Sanity Group GmbH ("Sanity Group") and the related private placement financing (the "Private Placement") with BT DE Investments Inc., a wholly-owned subsidiary of British American Tobacco ("BAT") at the Company's annual general and special meeting of shareholders (the "Shareholders") held on March 30, 2026 (the "Meeting"). Shareholders approved an ordinary resolution (the "Transaction Resolution") authorizing (i)

    3/30/26 8:30:00 PM ET
    $OGI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Six Flags Entertainment Appoints Richard Haddrill as Executive Chairman of the Board of Directors

    Six Flags Entertainment Corporation (NYSE:FUN) ("Six Flags" or the "Company"), North America's largest regional amusement park operator, today announced the appointment of Richard "Dick" Haddrill as Executive Chairman of the Six Flags Board of Directors, effective immediately. With Mr. Haddrill's appointment, Marilyn Spiegel will serve as Lead Independent Director. Over the last several months, Six Flags has taken decisive actions to improve performance, including appointing John Reilly as CEO in December 2025, accelerating the Company's portfolio optimization and improving its capital structure. Haddrill's appointment continues Six Flags' efforts to refresh the composition of its Board a

    3/25/26 8:00:00 AM ET
    $FUN
    Services-Misc. Amusement & Recreation
    Consumer Discretionary

    Organigram Announces Independent Proxy Advisory Firm ISS Recommends Organigram Shareholders Vote FOR the Acquisition of Sanity Group GmbH

    ISS Cites Compelling Strategic Rationale, Favorable Market Reaction, and Strong Institutional Confidence in Recommending Shareholders Vote FOR the Transaction Resolution Organigram Global Inc. (NASDAQ:OGI) (TSX:OGI), (the "Company" or "Organigram"), a leading licensed producer of cannabis, is pleased to announce that Institutional Shareholder Services Inc. ("ISS"), a leading independent proxy advisory firm, has recommended that holders of common shares of Organigram ("Shareholders") vote FOR the ordinary resolution (the "Transaction Resolution") to approve the indirect acquisition of Sanity Group GmbH ("Sanity") at the Company's Annual General and Special Meeting of Shareholders (the "Mee

    3/23/26 6:00:00 AM ET
    $OGI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACGN
    $APLS
    $APM
    $ASTI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Organigram Holdings Inc.

    SC 13D/A - ORGANIGRAM HOLDINGS INC. (0001620737) (Subject)

    12/10/24 7:10:15 PM ET
    $OGI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by JE Cleantech Holdings Limited

    SC 13D/A - JE Cleantech Holdings Ltd (0001905511) (Subject)

    11/25/24 6:13:31 AM ET
    $JCSE
    Miscellaneous manufacturing industries
    Consumer Discretionary

    Amendment: SEC Form SC 13G/A filed by Apellis Pharmaceuticals Inc.

    SC 13G/A - Apellis Pharmaceuticals, Inc. (0001492422) (Subject)

    11/22/24 4:16:13 PM ET
    $APLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACGN
    $APLS
    $APM
    $ASTI
    Financials

    Live finance-specific insights

    View All

    Kenvue to Announce First Quarter 2026 Results on May 7, 2026

    Kenvue Inc. (NYSE:KVUE) will announce its first quarter 2026 financial results before the market opens on May 7, 2026. Due to the pending transaction with Kimberly-Clark, Kenvue will not be hosting a quarterly conference call to review its financial results. The press release will be available on the company's website at investors.kenvue.com. About Kenvue Kenvue Inc. is the world's largest pure-play consumer health company by revenue. Built on more than a century of heritage, our iconic brands, including Aveeno®, BAND-AID® Brand, Johnson's®, Listerine®, Neutrogena® and Tylenol®, are science-backed and recommended by healthcare professionals around the world. At Kenvue, we realize the

    4/23/26 4:32:00 PM ET
    $KVUE
    Specialty Chemicals
    Consumer Discretionary

    Vir Biotechnology to Host Conference Call for First Quarter 2026 Financial Results

    Vir Biotechnology, Inc. (NASDAQ:VIR), today announced that it will host a conference call at 4:30 p.m. ET / 1:30 p.m. PT on Wednesday, May 6 to provide a corporate update and discuss its financial results for the first quarter ended March 31, 2026. The conference call may be accessed on the Events & Presentations page of the Vir Biotechnology website. About Vir Biotechnology Vir Biotechnology, Inc. is a clinical-stage biopharmaceutical company focused on powering the immune system to transform lives by discovering and developing medicines for serious infectious diseases and cancer. Its clinical-stage portfolio includes programs for chronic hepatitis delta and multiple PRO-XTEN® dual-mas

    4/23/26 4:05:00 PM ET
    $VIR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Crown Castle Reports First Quarter 2026 Results and Maintains Outlook for Full Year 2026

    HOUSTON, April 22, 2026 (GLOBE NEWSWIRE) -- Crown Castle Inc. (NYSE:CCI) ("Crown Castle") today reported results for the first quarter ended March 31, 2026, and maintained its full year 2026 Outlook, as reflected in the table below. (dollars in millions, except per share amounts)Current Outlook Midpoint(a)Full Year 2025 Actual Change% ChangeSite rental revenues(b)$3,850$4,049 $(199)(5)%Net income (loss)$780$444 $33676%Net income (loss) per share—diluted$1.80$1.01 $0.7978%Adjusted EBITDA(b)(c)$2,690$2,863 $(173)(6)%AFFO(b)(c)$1,920$1,904 $161%AFFO per share(b)(c)$4.43$4.36 $0.072% (a)Reflects midpoint of full year 2026 Outlook as issued on April 22, 2026, and unchanged from previous full y

    4/22/26 4:15:00 PM ET
    $CCI
    Real Estate Investment Trusts
    Real Estate